Novo Nordisk faces challenges in hemophilia market

"Snapping up market share in bleeding disorders won't be easy," Fierce Biotech's Tracy Staton notes, regarding FDA BLA approval for Novo Nordisk's (NVO +1.7%) NovoEight.

Entrenched competitors in the hemophilia market include Baxter (BAX) — whose market position could come under pressure in the future thanks to competition from Biogen's (BIIB) long-acting clotting factor therapies (see here and here) — and Pfizer (PFE).

Nevertheless, "NovoEight's approval is a step toward replacing [expected] lost revenues" from NovoSeven.

Other relevant info cited by Staton: In June, the FDA "refused to approve rFXIII ... for the rare bleeding disorder congenital factor XIII deficiency [citing] problems with NVO's manufacturing, and last year, the drugmaker canned another potential entry in hemophilia, vatreptacog alfa, after some patients developed antibodies to the treatment."

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs